Long-term follow-up is ongoing to investigate treatment safety and efficacy persists and to determine whether repeated treatment with ProTrans will be necessary for maintaining endogenous insulin production, thereby slowing disease progression and reducing the risk of type 1 diabetes-associated complications. The gene discussed is INS; the disease is type 1 diabetes mellitus.